SCHEMBL17844461

SCHEMBL17844461

Cn1nccc1C(c1cccnc1C(F)(F)F)N1CCN(CCc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.47
OPRM1 P35372 5/20 0.47
KCNH2 Q12809 3/20 0.47
HTR1A P08908 2/20 0.36
SLC6A3 Q01959 1/20 0.36
HSD11B1 P28845 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD4 P21917 1/20 0.36
HTR2A P28223 1/20 0.36
DRD2 P14416 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17844501 0.82 SIGMAR1 (0.46) SIGMAR1OPRM1KCNH2SLC6A3HDAC4
SCHEMBL17844467 0.82 SIGMAR1 (0.49) SIGMAR1OPRM1KCNH2
SCHEMBL17844483 0.81 SIGMAR1 (0.44) SIGMAR1OPRM1KCNH2HTR1ASLC6A3
SCHEMBL17865309 0.81 SLC1A3 (0.47) SIGMAR1OPRM1HTR1ASLC6A3DRD2
SCHEMBL17865306 0.80 HDAC4 (0.51) SIGMAR1OPRM1KCNH2HTR1ASLC6A3
SCHEMBL17865225 0.80 SIGMAR1 (0.42) SIGMAR1OPRM1KCNH2HDAC4HDAC1
SCHEMBL17865264 0.80 KCNH2 (0.54) SIGMAR1KCNH2
SCHEMBL17865263 0.79 SIGMAR1 (0.45) SIGMAR1OPRM1SLC6A3HDAC4HDAC1
SCHEMBL17844556 0.78 SIGMAR1 (0.44) SIGMAR1KCNH2HDAC4HDAC1
SCHEMBL17844469 0.77 SLC1A2 (0.46) SIGMAR1HTR1ASLC6A3DRD2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US claimed
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
EP-3233830-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN Laboratorios Del. Dr. Esteve, S.A. (ES) 2017-10-25 EP disclosed
WO-2016096126-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, OPRM1, SIGMAR1 SIGMAR1 3/4885OPRM1 2/4885KCNH2 633/4885
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain OPRD1, OPRM1, SIGMAR1 SIGMAR1 3/4885OPRM1 2/4885KCNH2 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.